Setmelanotide analysis: metabolic syndrome severity fell after about a year of treatment in POMC and LEPR deficiency
A post-hoc analysis of the phase 3 setmelanotide trials, published in the Journal of Clinical Endocrinology and Metabolism, found metabolic syndrome severity scores improved in 18 patients with POMC or LEPR deficiencies after about a year of treatment, though most metabolic parameters were already in the normal range at baseline.
The analysis, by Wabitsch and colleagues and published online October 19, 2026 in the Journal of Clinical Endocrinology and Metabolism, pooled patients from the phase 3 trials of setmelanotide in obesity caused by proopiomelanocortin (POMC) deficiency (NCT02896192) or leptin receptor (LEPR) deficiency (NCT03287960), rare genetic conditions that impair melanocortin-4 receptor signaling. Setmelanotide, an MC4R agonist, is already approved for chronic weight management in these deficiencies; this analysis asked whether treatment also shifted metabolic risk.
Of the 21 patients enrolled in the trials, 18 had complete metabolic parameter data and were included. The investigators tracked standard metabolic parameters and a metabolic syndrome severity score based on body mass index (MetS-Z-BMI) at baseline and after roughly one year of treatment, with subgroup analyses by sex, age, genotype, and treatment response.
The overall baseline mean MetS-Z-BMI score was 1.49 (SD 1.33), and group means for most metabolic parameters were already within the normal range at baseline, with weight-related measures, fasting glucose, and triglycerides the exceptions. After about one year, the mean change in MetS-Z-BMI score was -1.05 (SD 0.88), and most patients had improved on at least one metabolic parameter by week 52. Reductions were significantly greater in patients who met weight-loss thresholds than in those who did not (P = .0187), and in POMC deficiency compared with LEPR deficiency (P = .0278).
The findings carry clear limits. Eighteen patients is a small cohort, this is a post-hoc analysis of earlier trials rather than a dedicated metabolic-outcome study, most participants were metabolically healthy at baseline, and the subgroup comparisons are exploratory. The authors frame the results as an association between setmelanotide treatment and reduced metabolic syndrome severity in these rare deficiency populations, not as evidence for broader use.
Original sources
ClinicalTrials.gov: NCT02896192 (setmelanotide in POMC deficiency)
ClinicalTrials.gov: NCT03287960 (setmelanotide in LEPR deficiency)